secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2025-03-07T23:59:59+00:00
Accession:  0001093557-25-000047
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

DexCom receives FDA warning letter for manufacturing deficiencies; reaffirms FY2025 revenue guidance
--------------------------------------------------------------------------------

- FDA warning letter cites non-conformities in manufacturing processes and quality systems at San Diego and Mesa facilities.
- Inspections occurred Oct–Nov 2024 (San Diego) and June 2024 (Mesa); company had submitted Form 483 responses.
- Warning letter does not restrict production, distribution, or 510(k) clearance; no recall required.
- DexCom expects no material impact on manufacturing capacity or FY2025 revenue guidance issued Feb 13, 2025.
- Company is preparing written response and intends corrective actions; resolution timeline uncertain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355725000047/0001093557-25-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355725000047/dxcm-20250304.htm
  HTML page:      https://secwatch.observer/filing/0001093557-25-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer